The main purpose of this study is to evaluate the efficacy of the study drug LY900014
compared to insulin lispro, both in combination with insulin glargine or insulin degludec, in
adults with type 1 diabetes (T1D).
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Your participation in the main study may last up to 39 or 65 weeks, depending on treatment assignment. You may also be asked to return for two additional blood tests during a follow-up period of up to 26 weeks.
Participant must have been diagnosed with type 1 diabetes at least 1 year ago
Participant must already be using a long-acting insulin
Participant must already be using a rapid-acting insulin
Participant must not have used any other antihyperglycemic medications or therapies (inhaled, oral or injectable) within the last 90 days
Participant must not have had emergency treatment for very low blood glucose or poor blood glucose control in the last 6 months.
To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled. This website is not optimized for your browser, as configured.